Families caring for someone with advanced Alzheimer’s disease face a daily struggle with agitation, a symptom that can include pacing, yelling, and physical aggression. A completed randomized placebo-controlled trial tested dronabinol, a pill form of synthetic THC, in 75 patients over three weeks to measure whether it could reduce those behaviors. That study, which enrolled participants from 2017 to 2024, is now joined by a newer Phase 2/3 trial and at least two other registered studies of cannabis-based compounds targeting the same problem, creating an active pipeline of clinical research with direct consequences for patients and caregivers.
Why synthetic THC trials for Alzheimer’s agitation matter right now
Agitation is one of the most distressing symptoms of late-stage Alzheimer’s, and existing treatments often come with heavy sedation or other side effects that can worsen quality of life. The search for targeted alternatives has pushed researchers toward synthetic cannabinoids, compounds that interact with the brain’s endocannabinoid system in ways that may calm agitation without the blunt sedation of traditional antipsychotics.
The completed randomized controlled trial of dronabinol for agitation in Alzheimer’s disease, described in a peer-reviewed journal report, represents the strongest clinical evidence so far for this approach. The study enrolled 75 participants in a double-blind, placebo-controlled design with co-primary outcomes measured by the Pittsburgh Agitation Scale. Dronabinol is a synthetic version of THC, the psychoactive compound in cannabis, already approved by the FDA for other medical uses, which gives regulators and clinicians a baseline understanding of its pharmacology and known risks.
A separate question is whether dronabinol performs better than nabilone, another synthetic cannabinoid that has also been tested for Alzheimer’s agitation. Because dronabinol has a shorter half-life than nabilone, some researchers have hypothesized it may produce less cumulative sedation over repeated doses. That pattern would be testable in a head-to-head comparison of the existing trial arms, but full datasets from both compounds have not yet been published in enough detail to draw that conclusion. Until complete adverse-event tables and endpoint data are released, the relative advantages of each compound remain an open question rather than a settled finding.
Three registered trials and a corporate filing map the research pipeline
The clinical evidence base extends well beyond a single completed study. The THC-AD trial, registered on ClinicalTrials.gov as NCT02792257, established the randomized, double-blind, placebo-controlled framework that subsequent studies have followed. Its three-week treatment window was designed to capture short-term changes in agitation scores, though it left longer-term safety and efficacy unanswered, including whether benefits persist or diminish over months.
A Phase 2/3 study of dronabinol oral solution, listed under the identifier NCT07422311, signals that development of dronabinol formulations for this indication is continuing. The newer trial uses a liquid formulation rather than a capsule, which could affect dosing precision and absorption in elderly patients who often have difficulty swallowing pills. A solution can be titrated more flexibly, potentially allowing clinicians to adjust doses in smaller increments to balance agitation relief with cognitive or sedative side effects.
Running in parallel is the Nabilone for Agitation Blinded Intervention Trial, known as NAB-IT and registered as NCT04516057, which is testing nabilone, sold under the brand name CESAMET. The drug’s FDA-approved label already warns of central nervous system effects and interactions with sedatives, a profile that makes careful dose calibration essential in frail, older patients. A separate peer-reviewed trial of nabilone in moderate-to-severe Alzheimer’s agitation has provided concrete effect estimates and adverse-event data, including notable sedation rates that may limit routine use outside of closely monitored settings.
A third active study, the Clinical Trial on Agitation in Alzheimer’s Dementia, or CALMA, is evaluating a THC-based formulation called IGC-AD1 in a Phase 2 multicenter randomized, double-blind, placebo-controlled design. IGC Pharma described the trial’s design and progress in its annual report filed with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2025. That corporate disclosure gives investors and regulators a paper trail for what the company has committed to regarding trial design and timeline, including planned enrollment numbers and primary agitation endpoints.
The FDA has approved both dronabinol and nabilone for other indications, but the agency draws a clear line between these approved synthetic cannabinoid drugs and unapproved cannabis products sold through state-legal dispensaries. That regulatory distinction matters because it means these trial compounds have already cleared basic safety thresholds for human use, even though their effectiveness for Alzheimer’s agitation is still being evaluated. Families should not assume that over-the-counter or dispensary cannabis products will mirror the dosing, purity, or risk profile of the formulations being tested in these controlled trials.
Gaps in data that families and clinicians should track
Several significant unknowns limit what anyone can conclude from the current evidence. The completed THC-AD trial’s full numerical results and adverse-event tables are not yet available as a complete primary dataset beyond the published summary. Without those granular numbers, clinicians cannot fully assess how dronabinol’s side-effect profile compares to existing treatments or to nabilone, particularly in terms of falls, delirium, or cardiovascular events in frail older adults.
No primary investigator statements or raw endpoint data detail how individual patients responded over time, which would help clarify whether improvements in agitation were steady, fluctuating, or front-loaded in the first days of treatment. It is also unclear how many participants discontinued the study drug due to adverse effects versus lack of benefit, an important distinction for real-world prescribing decisions.
Another gap involves long-term outcomes. The core dronabinol study and similar short-duration trials are powered to detect changes over weeks, not months or years. Families and clinicians still lack evidence on whether chronic exposure to synthetic THC analogs might worsen cognition, increase fall risk, or interact with other commonly prescribed medications. Until extension studies or longer trials are completed and reported, these longer-horizon questions remain unanswered.
There is also limited information on how these drugs perform across diverse patient populations. Most Alzheimer’s agitation trials enroll participants who meet strict inclusion and exclusion criteria, which can filter out people with multiple chronic conditions, severe cardiovascular disease, or concurrent psychiatric diagnoses. As a result, the trial populations may not fully reflect the complexity of patients seen in everyday dementia care, making it difficult to generalize findings without caution.
What this evolving evidence means for caregivers and policy
For families, the current research pipeline offers cautious hope rather than an immediate solution. The existing dronabinol trial suggests that a subset of patients may experience meaningful reductions in agitation, but the magnitude of benefit, durability of response, and risk of sedation or confusion are still being quantified. Until more complete data are available, caregivers should view synthetic cannabinoid treatments as experimental options best pursued within clinical trials rather than as routine off-label prescriptions.
Clinicians, meanwhile, face pressure from families desperate for alternatives to antipsychotics and benzodiazepines. The emerging evidence base gives them a framework for discussing risks and uncertainties, emphasizing that synthetic THC analogs are being studied under tightly controlled conditions with careful monitoring. Where trial enrollment is possible, referring patients into these studies can provide access to potential benefits while contributing to the evidence needed to guide future standards of care.
Policymakers and regulators will also need to grapple with how to integrate any positive findings into practice guidelines. If one or more of these trials ultimately demonstrates a favorable balance of benefit and risk, agencies may be asked to consider label expansions, reimbursement decisions, and safeguards to prevent inappropriate use. Conversely, if the trials show limited benefit or unacceptable side effects, that outcome will also carry important lessons about the limits of cannabinoid-based strategies for neuropsychiatric symptoms in dementia.
For now, the most practical step for families and clinicians is to stay informed as results from THC-AD, NAB-IT, the dronabinol oral solution study, and CALMA move from registries and corporate filings into full peer-reviewed publications. Each new dataset will help clarify who, if anyone, stands to benefit most from synthetic THC analogs, at what doses, and with what trade-offs. Until those answers are clearer, nonpharmacologic strategies for managing agitation, along with judicious use of existing medications, remain the backbone of care for people living with advanced Alzheimer’s disease.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
